Polyglandular syndromes in internal medicine are characterized by a combination of lesions of endocrine and non-endocrine tissues. Autoimmune polyglandular syndrome type 2 (APS-2) is manifested by a combination of primary hypocorticism – adrenal insufficiency, autoimmune thyroid disease – Graves’ disease or hypothyroidism as the outcome of autoimmune thyroiditis. This pathology is the most common variant of polyglandular endocrinopathies. To diagnose APS at the current level, it is necessary to detect such a specific serological marker as antibodies to 21-hydroxylase in blood serum. The author observed a 57-year-old female patient with type 2 autoimmune polyglandular syndrome, manifested by hypothyroidism and hypocorticism. There is a history of thyroid resection for nodular form of chronic autoimmune thyroiditis 20 years ago with the outcome of hypothyroidism, later in 6 years with hypocorticism. She complained about postural vertigo, weakness. The condition deteriorated a month ago when the patient felt sore throat, symptoms of rhinitis. The autoimmune hemolytic anemia (AIHA) developed during the treatment of ARI with ergoferon. Over the past 5 years the patient has been admitted to the hematology department three times, whereas there was no necessity in admitting to the endocrinology department. While treating AIHA no other tissue damage was reported (hormonal or non hormonal) which is probably related to the unique antigenic structure of the red blood cell membrane. The membrane structure found in red blood cells does not occur in other tissues. The author believes that this form of anemia should be considered as an independent diagnosis, not as a part of APS-2. APS-2 and AIHA are two distinct, pathogenically independent diseases.
hypothyroidism, hypercortisolism, hemolysis, defect of immune regulation, polyglandular lesions, ergoferon, rituximab
1. Larina A. A., Shapovalyants O. S., Mazurina N. V., Troshina E. A. Diagnosis and treatment of autoimmune polyglandular syndrome in adults. Clinical medicine. 2012;(8):64-66.
2. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clinical and Experimental Immunology. 2004;137(2):225-233. doihttps://doi.org/10.1111/j.1365-2249.2004. 02561.x.
3. Smirnova E. N., Sarapulova O. N. Clinical and hormonal status of patients with autoimmune polyendocrinopathies in the Perm region. Perm Medical Journal. 2008;(2):61-63.
4. Larina A. A., Troshina E. A., Ivanova O. N. Association of the development of autoimmune polyglandular syndromes in adults with HLA class II gene polymorphism and predisposition to the development of chronic adrenal
5. Gubergrits N. B., Golubova O. A., Lyutsiferenko V. K. et al. Schmidt’s syndrome in the practice of an endocrinologist and gastroenterologist. Review of literature and clinical observation of a combination of Schmidt’s syndrome
6. Gaponova O. G. Autoimmune gastritis: controversial issues of pathogenesis, problems of diagnosis and therapy. Acute and emergency conditions in medical practice 2009;18(5):18-25.
7. Nuriddinova U. N., Zhumbaeva A. Autoimmune hemolytic anemia: mechanisms of development. Theoretical and Clinical Medicine. 2016;(4):117-119.
8. Shurkhina E. S., Tsvetaeva N. V., Kolodey S. V., et al. Density and deformability of erythrocytes in a patient with autoimmune hemolytic anemia with antiphospholipid syndrome at different periods of the disease. Hematology
9. Tsvetaeva N.V., Nikulina O.F., Shurkhina E.S. et al. New possibilities for treating resistant forms of autoimmune hemolytic anemia with rituximab. Hematology and Transfusiology. 2009;54(5):8-12.
10. Nikulina O. F., Tsvetaeva N. V., Shurkhina E. S. et al. Efficacy of treatment with rituximab in patients with AIHA with heat and cold agglutinins. Hematology and Transfusiology. 2016;61(1):59.
